<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="178">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01559922</url>
  </required_header>
  <id_info>
    <org_study_id>SUN-11-001</org_study_id>
    <nct_id>NCT01559922</nct_id>
  </id_info>
  <brief_title>Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction</brief_title>
  <official_title>A Phase 3 Randomized Placebo-Controlled Double-Blind Study of the Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suneva Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suneva Medical, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Artefill is safe and effective for the
      correction of atrophic facial acne scars.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2012</start_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of ASRS-based success</measure>
    <time_frame>6 months post-treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months post-treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Acne Scarring of the Face</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artefill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Administration of up to 2 study treatments administered 6 weeks apart</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artefill</intervention_name>
    <description>Administration of up to 2 study treatments administered 6 weeks apart</description>
    <arm_group_label>Artefill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be an outpatient, male or female subjects of any race, 18 years of age
             or older.  Female subjects of childbearing potential must have a negative urine
             pregnancy test result at Baseline and practice a reliable method of contraception
             throughout the study.

          2. Subject must have moderate to severe atrophic acne scars

          3. Subject must desire correction of his/her moderate to severe acne scarring.

          4. Subjects of all Fitzpatrick skin types are eligible.

          5. Subject must be willing to withhold additional aesthetic therapies to the face (eg,
             other soft tissue fillers: Restylane, Radiesse, Sculptra, and/or any resurfacing
             procedures for the duration of the study.

          6. Subject must be able to follow study instructions and likely to complete all required
             visits, as assessed by the Investigator.

          7. Subject must sign an IRB-approved Informed Consent form, Photographic Release Form,
             and the Authorization for Use and release of Health and Research Study Information
             (HIPAA) form prior to any study-related procedures being performed

        Exclusion Criteria:

          1. Female subjects that are pregnant (positive urine pregnancy test), breast-feeding, or
             who are of childbearing potential and not practicing a reliable method of birth
             control.

          2. Undergo facial treatments with any listed of the prohibited treatment/procedures
             and/or use of any other prohibited treatment/procedure within certain time periods.

          3. Have any skin pathology or condition that could interfere with the evaluation of the
             treatment areas, worsen due to the proposed treatment or require interfering topical,
             systemic or surgical therapy.

          4. Have a recent or current history of inflammatory skin disease, infection,
             cancerous/pre-cancerous lesion, unhealed wound or clinically significant acne in the
             proposed treatment areas.  Clinically significant acne is defined as a patient whom
             has &gt;3 active inflammatory acne lesions in either the right or left treatment area.

          5. Have a history of systemic granulomatous diseases active or inactive (eg, Sarcoid,
             Wegeners, TB, etc.) or connective tissue diseases (eg, lupus, dermatomyositis, etc.).

          6. Have hypertrophic acne scars, any evidence of keloid scarring, predominantly icepick
             scarring (defined as more than half of all scar area in either the left or right or
             treatment area) or sinus tract scars.

          7. Have a known hypersensitivity or previous allergic reaction to any of the components
             of the study device (including lidocaine or any amide-based anesthetic), or has a
             history of allergies to any bovine collagen products, including but not limited to
             injectable collagen, collagen implants, hemostatic sponges, and collagen-based
             sutures.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St.Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellesley</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 9, 2012</lastchanged_date>
  <firstreceived_date>March 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polymethyl Methacrylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
